Johnson & Johnson holds the cleaner structural position, with the lead spread across valuation and profitability. AstraZeneca does not offset that deficit through any equally strong structural edge elsewhere. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels.
The lead is spread across valuation and profitability, rather than sitting in one isolated gap. The overall score gap is 24 points in favour of Johnson & Johnson.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. AZN.L and JNJ share the same industry classification.
For a similarity-based comparison, see how AstraZeneca and Johnson & Johnson each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Pricing and operating quality both support the lead here.
Left means cheaper relative valuation. Higher means stronger structure.
Johnson & Johnson looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The multiple-based pricing edge comes from a trailing P/E that is 9.1 turns lower.
Capital efficiency adds support, with a 5.9-point ROIC advantage.
The lead is built on both valuation and profitability, making it broader than a single-dimension result.
Break down the AZN.L vs JNJ comparison across all dimensions with the full interactive tool.
Explore how AZN.L and JNJ each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.